Research progress of the immunoscore system in gastric cancer

doi:10.3760/cma.j.cn371439-20250509-00009

Abstract

Abstract:

The immunoscore system serves as a key indicator for evaluating the immune status and prognosis of cancer patients. Its prognostic evaluation and efficacy prediction function have been validated in various solid tumors. The immunoscore in gastric cancer is modulated by various factors, including the tumor microenvironment and the patient's intrinsic immune status. A comprehensive summary of its applications in prognosis prediction, selection of adjuvant therapeutic regimens, and treatment response assessment may offer novel perspectives and strategic guidance for the individualized management of gastric cancer.

Key words: Stomach neoplasms, Tumor microenvironment, Immunotherapy

Wang Yu, Li Yuanfei, Guo Yuntong. Research progress of the immunoscore system in gastric cancer[J]. Journal of International Oncology, 2026, 53(1): 62-64.

References 26

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834.
[2]	宫英博, 朱志, 王鑫, 等. 不同生物学行为对相同TNM分期进展期胃癌患者预后的影响[J]. 中华胃肠外科杂志, 2020, 23(10): 953-962. DOI: 10.3760/cma.j.cn.441530-20190926-00361.
[3]	Imen H, Amira H, Fatma K, et al. Prognostic value of immunoscore in colorectal carcinomas[J]. Int J Surg Pathol, 2024, 32(1): 58-65. DOI: 10.1177/10668969231168357.
[4]	Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680. DOI: 10.1038/s41568-020-0285-7.
[5]	Mastracci L, Fontana V, Queirolo P, et al. Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4⁺ tumor infiltrating lymphocytes and their in situ localization[J]. Cancer Immunol Immunother, 2020, 69(4): 653-662. DOI: 10.1007/s00262-020-02494-y. pmid: 32025849
[6]	Bieri U, Enderlin D, Buser L, et al. Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: a digital pathology study[J]. Front Oncol, 2022, 12: 964672. DOI: 10.3389/fonc.2022.964672.
[7]	Li G, Song Q, Cai A, et al. An immunoscore nomogram for predicting survival in patients with oesophageal cancer[J]. Aging (Albany NY), 2021, 13(6): 8762-8776. DOI: 10.18632/aging.202686.
[8]	Zhang L, Dong Q, Wang Y, et al. Global trends and risk factors in gastric cancer: a comprehensive analysis of the Global Burden of Disease Study 2021 and multi-omics data[J]. Int J Med Sci, 2025, 22(2): 341-356. DOI: 10.7150/ijms.104437. pmid: 39781526
[9]	Jiang Y, Zhang Q, Hu Y, et al. Immunoscore signature: a prognostic and predictive tool in gastric cancer[J]. Ann Surg, 2018, 267(3): 504-513. DOI: 10.1097/SLA.0000000000002116. pmid: 28002059
[10]	Jiang Y, Wang H, Wu J, et al. Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer[J]. Ann Oncol, 2020, 31(6): 760-768. DOI: 10.1016/j.annonc.2020.03.295. pmid: 32240794
[11]	Zhao R, Shen W, Zhao W, et al. Integrating radiomics, pathomics, and biopsy-adapted immunoscore for predicting distant metastasis in locally advanced rectal cancer[J]. ESMO Open, 2025, 10(3): 104102. DOI: 10.1016/j.esmoop.2024.104102.
[12]	El Sissy C, Kirilovsky A, Van den Eynde M, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy[J]. Clin Cancer Res, 2020, 26(19): 5198-5207. DOI: 10.1158/1078-0432.CCR-20-0337. pmid: 32669377
[13]	曾强. 新辅助直肠评分及活检免疫评分在直肠癌不同新辅助放化疗模式中的价值[D]. 北京: 中国医学科学院, 2023. DOI: 10.27648/d.cnki.gzxhu.2023.000336.
[14]	Ghiringhelli F, Bibeau F, Greillier L, et al. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti-PD1/PD-L1 immunotherapy in non-small cell lung cancer[J]. EBioMedicine, 2023, 92: 104633. DOI: 10.1016/j.ebiom.2023.104633.
[15]	Kim H, Heo YJ, Cho YA, et al. Tumor immune microenvironment is influenced by frameshift mutations and tumor mutational burden in gastric cancer[J]. Clin Transl Oncol, 2022, 24(3): 556-567. DOI: 10.1007/s12094-021-02714-6.
[16]	Yun S, Koh J, Nam SK, et al. Immunoscore is a strong predictor of survival in the prognosis of stage Ⅱ/Ⅲ gastric cancer patients following 5-FU-based adjuvant chemotherapy[J]. Cancer Immunol Immunother, 2021, 70(2): 431-441. DOI: 10.1007/s00262-020-02694-6.
[17]	Tan J, Wu Z, Liu Y, et al. Transcriptional profiling reveals H. pylori-associated genes induced inflammatory cell infiltration and chemoresistance in gastric cancer[J]. Front Immunol, 2025, 16: 1592558. DOI: 10.3389/fimmu.2025.1592558.
[18]	刘畅. 胃癌免疫评分与Tregs、PD-L1、MMR相关性及Tregs与免疫疗效关系探讨[D]. 承德: 承德医学院, 2023. DOI: 10.27691/d.cnki.gcdyx.2023.000027.
[19]	Yan H, Chen Y, Yang Z, et al. An immune cell signature is associated with disease-free survival and adjuvant chemosensitivity of patients with resectable gastric cancer[J]. Front Immunol, 2020, 11: 621623. DOI: 10.3389/fimmu.2020.621623.
[20]	Zeng D, Zhou R, Yu Y, et al. Gene expression profiles for a prognostic immunoscore in gastric cancer[J]. Br J Surg, 2018, 105(10): 1338-1348. DOI: 10.1002/bjs.10871. pmid: 29691839
[21]	Soeratram TTD, Beentjes I, Egthuijsen JMP, et al. A biopsy-based immunoscore in patients with treatment-naïve resectable gastric cancer[J]. Ther Adv Med Oncol, 2024, 16: 17588359241287747. DOI: 10.1177/17588359241287747.
[22]	Nie RC, Chen GM, Yuan SQ, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis[J]. Ann Surg Oncol, 2022, 29(4): 2324-2331. DOI: 10.1245/s10434-021-11050-6.
[23]	Dang Y, Ma M, Wang Y, et al. Carvedilol sensitizes chemotherapy by targeting STING to boost anti-tumor immunity[J]. Cell Rep, 2025, 44(5): 115572. DOI: 10.1016/j.celrep.2025.115572.
[24]	Chen T, Li X, Mao Q, et al. An artificial intelligence method to assess the tumor microenvironment with treatment outcomes for gastric cancer patients after gastrectomy[J]. J Transl Med, 2022, 20(1): 100. DOI: 10.1186/s12967-022-03298-7.
[25]	Zeng D, Li M, Zhou R, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures[J]. Cancer Immunol Res, 2019, 7(5): 737-750. DOI: 10.1158/2326-6066.CIR-18-0436. pmid: 30842092
[26]	杨鹏, 罗金梅, 罗萍, 等. 基于免疫细胞浸润的免疫评分模型预测早期胃癌免疫治疗效果及预后[J]. 实用肿瘤学杂志, 2024, 38(2): 121-130. DOI: 10.11904/j.issn.1002-3070.2024.02.007.